GLP‐1 receptor agonists improve the pathological features of NAFLD by enhancing insulin sensitivity, reducing body weight, and decreasing hepatic fat deposition and inflammation. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.